共 59 条
[1]
Mahato RI(2003)Emerging trends in oral delivery of peptide and protein drugs Crit Rev Ther Drug Carrier Syst. 20 153-214
[2]
Narang AS(2000)Drug-like properties and the causes of poor solubility and poor permeability J Pharmacol Toxicol Meth. 44 235-49
[3]
Thoma L(2009)Immunological risk of injectable drug delivery systems Pharm Res. 26 1303-14
[4]
Miller DD(2006)Protein aggregation and bioprocessing AAPS J. 8 E572-9
[5]
Lipinski CA(2002)Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Discov. 1 457-62
[6]
Jiskoot W(2009)Protein aggregation: pathways, induction factors and analysis J Pharm Sci. 98 2909-34
[7]
van Schie RM(2005)Protein drug stability: a formulation challenge Nat Rev Discov. 4 298-306
[8]
Carstens MG(2009)A critical review of methods for size characterization of non-particulate protein aggregates Curr Pharm Biotechnol. 10 359-72
[9]
Schellekens H(2009)Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality J Pharm Sci. 98 1201-5
[10]
Cromwell ME(2004)Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles Eur J Pharm Biopharm. 57 369-75